Could chickpea flour bread tame blood sugar spikes?

NCT ID NCT07716059

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This study looks at whether replacing some wheat flour with chickpea flour in bread can lower blood sugar rises after eating. Healthy adults and people with type 2 diabetes will eat bread made with finely or coarsely ground chickpea flour, and their blood sugar will be tracked continuously. The goal is to see if the legume flour, especially the coarser grind, leads to a gentler glucose response compared to regular white bread.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bread with 30% chickpea flour (finely milled or coarse)
What this could lead to
If it works, this could point toward a simple dietary swap—using legume flour in bread—to help manage blood sugar spikes after meals.
What could go wrong
This is a small, early-stage trial with only 35 participants, so results may not apply to everyone. The effect on long-term diabetes control is not tested here.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 35 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Cohort Healthy Participants Inclusion Criteria: * Age: Adults aged 18-35 years. * Health Status: Healthy individuals with no diagnosed chronic diseases, including diabetes, cardiovascular disease, or gastrointestinal disorders. * Body Mass Index (BMI): 18.5-27 kg/m² (normal to overweight range). * Fasting Glucose: Normal fasting plasma glucose (\<100 mg/dL or \<5.6 mmol/L). * No regular use of medications known to affect glucose metabolism (e.g., insulin, metformin, corticosteroids). * Ability and willingness to comply with study procedures, including continuous glucose monitoring and standardized test meals. * Informed Consent: Ability to understand and provide written informed consent. Exclusion Criteria: * Diagnosed chronic diseases: Diabetes (type 1 or type 2), cardiovascular disease, kidney or liver disease, gastrointestinal disorders (e.g., celiac disease, inflammatory bowel disease). * Abnormal glucose metabolism: Fasting plasma glucose ≥100 mg/dL (≥5.6 mmol/L) or HbA1c ≥5.7%. * Medication use: Regular use of medications that affect glucose metabolism, insulin sensitivity, or digestion (e.g., metformin, corticosteroids, GLP-1 analogs). * Allergies or intolerances: Allergy or intolerance to wheat, chickpeas, gluten, or other ingredients used in the study foods. * Pregnancy or lactation: Women who are pregnant, breastfeeding, or planning pregnancy during the study period. * Recent major weight change: Significant weight loss or gain (\>5% body weight) in the past 3 months. * Extreme physical activity: Competitive athletes or individuals engaging in extreme exercise regimens that could influence glucose metabolism. * Inability to comply: Individuals unable or unwilling to follow study procedures, including continuous glucose monitoring and standardized test meals. Cohort 2: Participants with Type 2 Diabetes Mellitus Men and women aged 40-75 years. Body mass index (BMI) \< 31 kg/m². Fasting plasma glucose \> 125 mg/dL. HbA1c \< 8.5%. Diagnosis of type 2 diabetes mellitus (T2DM) for at least 1 year before enrolment. Stable treatment with hypoglycaemic, lipid-lowering, and/or antihypertensive medications for at least 3 months prior to enrolment. Most participants will be recruited from the Diabetes Clinic of the 1st Propaedeutic Department of Internal Medicine, Laiko General Hospital. Exclusion criteria Endocrine, cardiovascular, pulmonary, renal, or gastrointestinal disorders that could affect study outcomes. Sensitivity, intolerance, or allergy to any ingredients of the study breads. Pregnancy or breastfeeding. Eating disorders. Use of medications or dietary supplements considered incompatible with the study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 1st Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 15772 Athens, Greece

    RECRUITING

    Athens, Attica, Greece

  • Harokopio University

    RECRUITING

    Athens, Attica, 17676, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.